Plus, news about Corbus and Astellas: Halia Therapeutics raises $30M Series C: The company, which is developing small molecules for inflammatory diseases, plans to use
Plus, news about Skye Bioscience and Vera Therapeutics: Ascendis Pharma, investors spin out eye care company: Eyconis, based in Redwood City, CA, will develop, manufacture
Plus, news about Prime Medicine, Sagimet Biosciences and Adicet Bio: Deerfield terminates rights to 2017 deal with Windtree Therapeutics: The biotech last year in-licensed Aerosurf,
Plus, news about Vera Therapeutics and Cellectar Biosciences: Alphamab Oncology, Glenmark ink licensing deal: Per the agreement, Glenmark will spend up to $700.8 million in
PMV Pharmaceuticals to cut 30% of its employees: The Princeton, NJ-based company had 62 full-time employees as of Feb. 28. It expects the cuts to extend
Plus, news about Prota Therapeutics and Vaxart: Windtree Therapeutics inks deal with Hong Kong group: Per the terms, Lee’s Pharmaceutical will pay Windtree up to
Ji Xing acquires Biogen’s experimental therapy for acute ischemic stroke: The Shanghai-based biopharma did not disclose the financial terms of the deal. Back in 2018,
Another China-US deal for AstraZeneca: The British drugmaker is paying $40 million upfront to Allorion Therapeutics to develop the company’s L858R mutated allosteric inhibitor as
Sofinnova Partners outlines European investment strategy: The venture capital firm aims to launch and accelerate biotech startups in Europe using a similar model to BiovelocITA,
Ideaya and Gilead will study a potential combo in bladder cancer. The South San Francisco-based company announced Monday that it plans to test its MAT2A